Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - stalevo
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpbdb3583748a144c4aaf24f2e42bc1ae4
identifier: http://ema.europa.eu/identifier
/EU/1/03/260/001-004
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Stalevo 50 mg/12.5 mg/200 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-bdb3583748a144c4aaf24f2e42bc1ae4
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/03/260/001-004
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - stalevo
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet:
Stalevo contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Stalevo is used for the treatment of Parkinson s disease. Parkinson s disease is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson s disease. Carbidopa and entacapone improve the antiparkinson effects of levodopa.
papaverine used to relax the muscles. Stalevo may make it harder for you to digest iron. Therefore, do not take Stalevo and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other. Stalevo with food and drink Stalevo may be taken with or without food. For some patients, Stalevo may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). Consult your doctor if you think this applies to you. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not breast-feed during treatment with Stalevo. Driving and using machines Stalevo may lower your blood pressure, which may make you feel light-headed or dizzy. Therefore, be particularly careful when you drive or when you use any tools or machines. If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, wait until you feel fully awake again before driving or doing anything else that requires you to be alert. Otherwise, you may put yourself and others at risk of serious injury or death. Stalevo contains sucrose Stalevo contains sucrose (1.2 mg/tablet). If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine. This medicine contains less than 1 mmol (23 mg) sodium per maximum recommended daily dose, that is to say essentially sodium-free .
If you are taking Stalevo 50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg tablets, do not take more than 10 tablets per day. Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you experience possible side effects. To open the bottle for the first time: open the closure, and then press with your thumb on the seal until it breaks. See picture 1. Picture 1 If you take more Stalevo than you should If you have accidentally taken more Stalevo tablets than you should, talk to your doctor or pharmacist immediately. In case of an overdose you may feel confused or agitated, your heart rate may be slower or faster than normal or the colour of your skin, tongue, eyes or urine may change. If you forget to take Stalevo Do not take a double dose to make up for a forgotten tablet. If it is more than 1 hour until your next dose: Take one tablet as soon as you remember, and the next tablet at the normal time. If it is less than 1 hour until your next dose: Take a tablet as soon as you remember, wait 1 hour, then take another tablet. After that carry on as normal. Always leave at least an hour between Stalevo tablets, to avoid possible side effects. If you stop taking Stalevo Do not stop taking Stalevo unless your doctor tells you to. In such a case your doctor may need to adjust your other antiparkinson medicines, especially levodopa, to give sufficient control of your symptoms. If you suddenly stop taking Stalevo and other antiparkinsonian medicines it may result in unwanted side effects. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger). Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the bottle and the carton. The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, titanium dioxide (E171), and yellow iron oxide (E172). What Stalevo looks like and contents of the pack Stalevo 50 mg/12.5 mg/200 mg: brownish or greyish red, round, convex unscored film-coated tablets marked with LCE 50 on one side. Stalevo comes in six different pack sizes (10, 30, 100, 130, 175 or 250 tablets). Not all pack sizes may be marketed. Marketing Authorisation Holder Orion Corporation Orionintie 1 FI-02200 Espoo Finland Manufacturer Orion Corporation Orion Pharma Joensuunkatu 7 FI-24100 Salo Finland For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder. Belgi /Belgique/Belgien Orion Pharma BVBA/SPRL T l/Tel: +32 (0)15 64 10 Lietuva UAB Orion Pharma Tel. +370 5 276 9 Orion Pharma Poland Sp z.o.o. Tel.: + 48 22 8333Luxembourg/Luxemburg Orion Pharma BVBA/SPRL T l/Tel: +32 (0)15 64 10 esk republika Orion Pharma s.r.o. Tel: +420 234 703 Magyarorsz g Orion Pharma Kft. Tel.: +36 1 239 9Danmark Orion Pharma A/S Tlf: +45 8614 0Malta Salomone Pharma Tel: +356 21220Deutschland Orion Pharma GmbH Tel: +49 40 899 6Nederland Orion Pharma BVBA/SPRL T l/Tel: +32 (0)15 64 10 Eesti Orion Pharma Eesti O Tel: +372 66 44 Norge Orion Pharma AS Tlf: +47 40 00 42
Orion Pharma Hellas M.E. .E : + 30 210 980 3 sterreich Orion Pharma GmbH Tel: +49 40 899 6Espa a Orion Pharma S.L. Tel: + 34 91 599 86 Polska Orion Pharma Poland Sp z.o.o. Tel.: + 48 22 8333France Orion Pharma T l: +33 (0) 1 85 18 00 Portugal Orionfin Unipessoal Lda Tel: + 351 21 154 68 Hrvatska Orion Pharma d.o.o. Tel: +386 (0) 1 600 8Rom nia Orion Corporation Tel: +358 10 4Ireland Orion Pharma (Ireland) Ltd. c/o Allphar Services Ltd. Tel: +353 1 428 7Slovenija Orion Pharma d.o.o. Tel: +386 (0) 1 600 8 sland Vistor hf. S mi: +354 535 7Slovensk republika Orion Pharma s.r.o Tel: +420 234 703 Italia Orion Pharma S.r.l. Tel: + 39 02 67876Suomi/Finland Orion Corporation Puh./Tel: +358 10 4 Lifepharma (ZAM) Ltd .: +357 22056Sverige Orion Pharma AB Tel: +46 8 623 6Latvija Orion Corporation Orion Pharma p rst vniec ba Tel: +371 20028United Kingdom (Northern Ireland) Orion Pharma (Ireland) Ltd. c/o Allphar Services Ltd. Tel: +353 1 428 7This leaflet was last revised in. Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-bdb3583748a144c4aaf24f2e42bc1ae4
Resource Composition:
Generated Narrative: Composition composition-en-bdb3583748a144c4aaf24f2e42bc1ae4
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/03/260/001-004status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - stalevo
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpbdb3583748a144c4aaf24f2e42bc1ae4
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpbdb3583748a144c4aaf24f2e42bc1ae4
identifier:
http://ema.europa.eu/identifier
/EU/1/03/260/001-004type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Stalevo 50 mg/12.5 mg/200 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en